title: Head and neck melanoma in the sentinel lymph node era.
abstract: OBJECTIVE
  To determine whether, in the era of sentinel lymph node (SLN) biopsy, head and neck melanoma (HNM) has a poorer outcome than melanomas at other sites (OMS).
  
  
  METHODS
  Prospective database, 1994 to 2004. Characteristics and outcomes of patients with HNM vs those with OMS were analyzed by Fisher test, paired t test, and chi(2) test.
  
  
  METHODS
  Tertiary referral center.
  
  
  METHODS
  A total of 755 patients with melanoma who had undergone SLN biopsy.
  
  
  METHODS
  Differences between patients with HNM and those with OMS.
  
  
  RESULTS
  A total of 17.4% of patients had HNM vs 82.6% with OMS. There was a male HNM preponderance: 68.7% vs 50.3% for females (P < .01). Patients with HNM were older (mean [SD] age, 57.1 [16.6] years vs 53.3 [16.2] years; P < .01). There were fewer cases of superficial spreading melanoma in patients with HNM (29.0% vs 53.7%; P < .01). There were more diagnoses of lentigo maligna in patients with HNM (26.0% vs 1.9%; P < .01). The mean thickness of the primary lesion was 2.32 (1.9) mm vs 2.31 (2.9) mm; P = .49. Fewer patients with HNM had Clark level involvement lower than level IV (13.3% vs 24.0%; P < .01). More SLNs were harvested from patients with HNM (3.72 [3.2] vs 2.89 [2.6]; P < .01), but a lower percentage of positive SLNs was found (9.2% vs 16.0%; P < .05). There was no difference in local, regional, or distant recurrence (5.3%, 6.9%, and 5.3%, respectively, in patients with HNM and 3.4%, 5.5%, and 6.7%, respectively, in patients with OMS). The 2- and 5-year survival rates for patients with HNM were 96.2% and 72.6%, respectively, vs 93.6% and 79.0%, respectively, in patients with OMS (P = .40).
  
  
  CONCLUSIONS
  Most patients with HNM are older males with more SLNs harvested. They do not seem to have poorer outcome than patients with OMS.
authors.affiliation: Department of Surgery, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, 410 W 10th Avenue, Columbus, OH 43210, USA. Doreen.Agnese@osumc.edu
authors.forename: Doreen M
authors.initials: DM
authors.lastname: Agnese
authors.forename: Rebecca
authors.initials: R
authors.lastname: Maupin
authors.forename: Bryan
authors.initials: B
authors.lastname: Tillman
authors.forename: Rodney D
authors.initials: RD
authors.lastname: Pozderac
authors.forename: Cynthia
authors.initials: C
authors.lastname: Magro
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Walker
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D016208:Databases, Factual; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008297:Male; D008545:Melanoma / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D021701:Sentinel Lymph Node Biopsy; D015996:Survival Rate